Boothwyn Pharmacy recalled 8 vials of Fluorescein 2% Ophthalmic Solution on July 9, 2025. The recall occurred due to the drug being subpotent, posing potential health risks. Consumers should stop using the product immediately and seek guidance from their healthcare provider.
Subpotent Drug
Consumers and healthcare providers should stop using this product immediately. Contact Boothwyn Pharmacy LLC or your healthcare provider for guidance. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
The recalled product is Fluorescein 2% Ophthalmic Solution in 3 ML vials. The specific model number is 06092025@23 BUD 09/09/2025. It was distributed nationwide in the U.S.
The product is classified as subpotent, which means it may not provide the intended therapeutic effect. This condition can pose significant health risks, especially for individuals relying on the medication.
No specific injuries or incidents have been reported related to this recall. The potential for health risks remains due to the subpotency of the drug.
Stop using the recalled product immediately. Contact Boothwyn Pharmacy LLC or your healthcare provider for further guidance.
Consumers can reach Boothwyn Pharmacy at 800-476-7496 for assistance regarding the recall. Additional information is available at the FDA's enforcement page.
Glenmark Pharmaceuticals Inc. recalled 13,824 tubes of Azelaic Acid Gel on September 17, 2025. The recall stems from market complaints regarding a gritty texture. Consumers should stop using the product immediately and contact their healthcare provider.
Skin MD by Dr Monika Kiripolsky recalled its Body Acne Cleanser on September 12, 2025. The recall follows the discovery of elevated benzene levels in the product. This contamination poses a high health risk to consumers in California and Georgia.
Private Label Skin Care recalled its Micronized BPO Gel Cleanser 10% on September 12, 2025. Elevated benzene levels prompted the recall in California and Georgia. Consumers must stop using the product immediately and seek guidance from healthcare providers.